Get the Stockscreener App
121.06
0.48%
0.53
Neurocrine Biosciences Inc stock is traded at $121.06, with a volume of 259.78K.
It is up +0.48% in the last 24 hours and up +6.24% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$120.53
Open:
$120.01
24h Volume:
259.78K
Relative Volume:
0.28
Market Cap:
$12.13B
Revenue:
$2.12B
Net Income/Loss:
$339.20M
P/E Ratio:
65.09
EPS:
1.86
Net Cash Flow:
$494.60M
1W Performance:
+4.23%
1M Performance:
+6.24%
6M Performance:
-13.93%
1Y Performance:
+7.71%
1-Day Range:
$119.08
$121.48
1-Week Range:
$119.08
$131.25
52-Week Range:
$103.63
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences' SWOT analysis: navigating challenges in a competitive biotech stock landscape - Investing.com UK
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia - The Pharma Letter
New York State Common Retirement Fund Has $20.71 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia - PR Newswire
Cantor Fitzgerald Has Weak Estimate for NBIX FY2024 Earnings - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript - MSN
abrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine shares target upgraded, market perform rating on positive outlook By Investing.com - Investing.com Australia
Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Mirae Asset Global Investments Co. Ltd. Acquires 9,601 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 - GlobeNewswire Inc.
Earnings call: Neurocrine Biosciences reports strong Q3 growth, plans ahead - Investing.com
Neurocrine: Q3 Earnings Snapshot - The Pioneer
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates - MSN
Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback - MSN
Forsta AP Fonden Sells 10,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap UpShould You Buy? - MarketBeat
Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance - PR Newswire
China Universal Asset Management Co. Ltd. Acquires 7,597 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences' (NBIX) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences - Benzinga
Mediolanum International Funds Ltd Purchases 13,809 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges By Investing.com - Investing.com South Africa
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Stanley Laman Group Ltd. Buys 10,088 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NBIX) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart
Neurocrine Bio stock retains Outperform rating at Oppenheimer with focus on Ingrezza and upcoming PDUFA dates - Investing.com Canada
Allspring Global Investments Holdings LLC Sells 20,614 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Leerink Partnrs Issues Negative Estimate for NBIX Earnings - MarketBeat
State Street Corp's Strategic Acquisition in Neurocrine Bioscien - GuruFocus.com
Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $114.00 at BMO Capital Markets - MarketBeat
Brokers Issue Forecasts for Neurocrine Biosciences, Inc.'s Q4 2024 Earnings (NASDAQ:NBIX) - MarketBeat
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Tourette Syndrome Drug Market 2024-2034- Abide Therapeutics Inc, Catalyst Pharmaceuticals Inc, Neurocrine Biosciences In – IndiaPolitics.com - IndiaPolitics.com
Neurocrine Biosciences appoints new CEO with revised compensation - Investing.com India
Neurocrine Biosciences appoints new CEO with revised compensation By Investing.com - Investing.com Australia
Tardive Dyskinesia Treatment Market Industry Detailed - openPR
Sleep-Wake Disorder Market 2031 | Key Brands -Jazz Pharmaceuticals, Koninklijke Philips N.V., Merck KGaA, Neurocrine Bio – IndiaPolitics.com - IndiaPolitics.com
Learn to Evaluate (NBIX) using the Charts - Stock Traders Daily
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):